Kymera Therapeutics (KYMR) PT Raised to $97 at Brookline Capital Markets
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts KYMR Hot Sheet
Price: $127.51 --0%
Rating Summary:
26 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 14 | New: 9
Rating Summary:
26 Buy, 4 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 14 | New: 9
Join SI Premium – FREE
Brookline Capital Markets analyst Leah Rush Cann raised the price target on Kymera Therapeutics (NASDAQ: KYMR) to $97.00 (from $90.00) while maintaining a Buy rating.
You May Also Be Interested In
- BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $94 at Oppenheimer
- Kymera Therapeutics (KYMR) PT Raised to $140 at Oppenheimer
- Barclays upgrades Bloom Energy to Overweight with $289 target
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
